253 related articles for article (PubMed ID: 18663817)
1. CYP2D6 pharmacogenomics of tamoxifen treatment.
Technol Eval Cent Assess Program Exec Summ; 2008 May; 23(1):1-4. PubMed ID: 18663817
[No Abstract] [Full Text] [Related]
2. CYP2D6 pharmacogenomics of tamoxifen treatment.
; ;
Technol Eval Cent Assess Program Exec Summ; 2014 Jan; 28(8):1-4. PubMed ID: 24730084
[No Abstract] [Full Text] [Related]
3. Modification of tamoxifen response: what have we learned?
Lash TL; Ahern TP; Cronin-Fenton D; Garne JP; Hamilton-Dutoit S; Kvistgaard ME; Rosenberg CL; Silliman RA; Sørensen HT
J Clin Oncol; 2008 Apr; 26(10):1764-5; author reply 1765-6. PubMed ID: 18375910
[No Abstract] [Full Text] [Related]
4. The ethics of CYP2D6 testing for patients considering tamoxifen.
Hartman AR; Helft P
Breast Cancer Res; 2007; 9(2):103. PubMed ID: 17433116
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.
Stingl JC; Parmar S; Huber-Wechselberger A; Kainz A; Renner W; Seeringer A; Brockmöller J; Langsenlehner U; Krippl P; Haschke-Becher E
Curr Med Res Opin; 2010 Nov; 26(11):2535-42. PubMed ID: 20849243
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
Gaston C; Kolesar J
Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
[TBL] [Abstract][Full Text] [Related]
8. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 genotype and tamoxifen response.
Rae JM; Goetz MP; Hayes DF; Ingle JN; Li L; Storniolo AM; Stearns V; Flockhart DA
Breast Cancer Res; 2005 Jul; 7(5):E6. PubMed ID: 16168100
[No Abstract] [Full Text] [Related]
10. Pharmacogenetics of breast cancer therapies.
Hertz DL; McLeod HL; Hoskins JM
Breast; 2009 Oct; 18 Suppl 3():S59-63. PubMed ID: 19914545
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.
Margolin S; Lindh JD; Thorén L; Xie H; Koukel L; Dahl ML; Eliasson E
Pharmacogenomics; 2013 Apr; 14(6):613-22. PubMed ID: 23570465
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
13. Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?
Peppercorn J; A Carey L
Expert Rev Anticancer Ther; 2008 Feb; 8(2):191-4. PubMed ID: 18279059
[TBL] [Abstract][Full Text] [Related]
14. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
[TBL] [Abstract][Full Text] [Related]
15. Update on CYP2D6 and its impact on tamoxifen therapy.
Goetz MP
Clin Adv Hematol Oncol; 2010 Aug; 8(8):536-8. PubMed ID: 20966889
[No Abstract] [Full Text] [Related]
16. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
Goetz MP; Kamal A; Ames MM
Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
[TBL] [Abstract][Full Text] [Related]
17. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
[TBL] [Abstract][Full Text] [Related]
18. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Goetz MP; Sangkuhl K; Guchelaar HJ; Schwab M; Province M; Whirl-Carrillo M; Symmans WF; McLeod HL; Ratain MJ; Zembutsu H; Gaedigk A; van Schaik RH; Ingle JN; Caudle KE; Klein TE
Clin Pharmacol Ther; 2018 May; 103(5):770-777. PubMed ID: 29385237
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies.
Johnson JA; Hamadeh IS; Langaee TY
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638249
[No Abstract] [Full Text] [Related]
20. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
